Search Results - "Nie, Chenpan"

323 Immunogenic syngeneic model MC38-OVA for the preclinical evaluation of immune evasion and checkpoint blockade by Wang, Jessie, Lian, Kaixia, Zheng, Jia, Nie, Chenpan, An, Annie, Li, Henry

“…BackgroundThe development of immuno-oncology (I/O) therapeutics has revolutionized the cancer treatment landscape. Despite this achievement, the mechanism…”
Get full text

Abstract A009: Establishment and application of a series of systemic bioluminescent hematologic cell line derived xenograft models by Song, Yanrui, Nie, Chenpan, Yang, Tao, Yin, Yinfei, Li, Henry Qixiang, Ouyang, Davy Xuesong

“…Background: Hematologic malignancies, including leukemia, multiple myeloma and lymphoma, are at the forefront of immunotherapeutic innovations. Fueled by FDA…”
Get full text

Abstract 5615: Anti-human CD47 antibody Hu5F9 inhibits MC38 tumor growth in hCD47/hSIRPα double knock-in mice by He, Daniel Xianfei, Nie, Chenpan, Zheng, Lei, Sun, Ruilin, An, Annie Xiaoyu, Li, Henry Q. x., Ouyang, Davy Xuesong

“…Introduction: CD47 is broadly expressed on all normal cells or tissues, such as hematopoietic cells, T cells, B cells, monocytes, thymocytes, and platelets as…”
Get full text

Abstract 538: Establishment of PARP inhibitor-induced resistant patient-derived ovarian cancer xenograft models by Hua, Li, Li, Shuang, Nie, Chenpan, Chen, Xiaobo, Sheng, Guo, Bourre, Ludovic, Wang, Jingjing

“…Introduction: Poly (ADP-ribose) polymerases (PARPs) can recruit DNA repair effectors and cope with DNA single-strand breaks. For DNA double-strand breaks…”
Get full text

Abstract 5264: KRASG12C inhibition synergizes with checkpoint blockade in KRASG12C-mutated tumor model by Hua, Li, Li, Shuang, Nie, Chenpan, Zhang, Chenfei, Bourre, Ludovic, Wang, Jingjing

“…Introduction: The KRASG12C mutation is found in 14% of non-small cell lung cancer (NSCLC) and 3% of colorectal cancer (CRC). Sotorasib (AMG510), which…”
Get full text

Abstract 5614: Combination of anti-TIGIT and anti-PD-1 antibodies enhance antitumor response in a PD-1/TIGIT double HuGEMM™ model engrafted with mouse syngeneic tumors by He, Daniel Xianfei, Nie, Chenpan, Zheng, Lei, Sun, Ruilin, Zhang, Mingkun, An, Annie Xiaoyu, Ju, Cunxiang, Li, Henry Q. X., Ouyang, Davy Xuesong

“…Introduction: Ample clinical and preclinical evidence have shown the remarkable antitumor effects of anti-PD-1 antibodies. However, the fact that only around…”
Get full text

Abstract 5118: STING agonist and TLR7/8 agonist overcome anti-PD-1 resistance mediated by loss of β2M by Hua, Li, Nie, Chenpan, Lin, Jie, An, Annie Xiaoyu, Bourre, Ludovic, Wang, Jingjing

“…Introduction: PD-1 blockade has achieved great success in the clinic. However, only a small subset of patients benefits from the treatment and most responders…”
Get full text

Abstract 4221: Characterization of OVA-expressing immunogenic syngeneic tumor models for immune checkpoint inhibitor evaluation by Nie, Chenpan, Zhang, Yi, Zheng, Jia, An, Annie X., Zhou, Jun, Li, Henry Q.X., Wang, Jingjing

“…BACKGROUND: Syngeneic mouse tumor models are widely used as preclinical models for immuno-oncology (I/O) research. However, their response to immune checkpoint…”
Get full text

Abstract 617: MEK inhibitor rescued the efficacy of PD-1 blocker in STK11/LKB1 mutated colorectal cancer model by Liu, Demi X., Zhou, Jun, Nie, Chenpan, An, Annie X., Li, Henry Q.X., Wang, Jingjing

“…Introduction: The mechanism of action of primary resistance to PD-1 blockade is largely unknown, however STK11/LKB1 alterations have been reported to have a…”
Get full text

Abstract 401: Developing KRAS G12C inhibitor-resistant tumor models for efficacy evaluation of next-generation anticancer therapies by Zhou, Jun, Ye, Zi, Bo, Ning, Zhang, Dan, Hua, Li, Nie, Chenpan, Wang, Jingjing, Kumari, Rajendra, Price, Leo, Xu, Xiaoxi

“…Background: AMG510, a novel KRAS G12C mutation-specific inhibitor approved in 2021 by FDA, was the first therapy to directly target the KRAS oncoprotein in…”
Get full text